CV Science

david monchaud PhD Chemical Biology

Course and current status

2023       CNRS Senior Researcher (1^st class, DR1) - CNRS UMR6302

ICMUB, Dijon, France.

2017       CNRS Senior Researcher (2^nd class, DR2) - CNRS UMR6302

ICMUB, Dijon, France.

2009       CNRS Research fellow (1^st class, CR1) - CNRS UMR6302

ICMUB, Dijon, France. Lab. of Pr. Franck Denat.

2007       CNRS Research fellow (2^nd class, CR2) - CNRS UMR176

Institut Curie, Orsay, France. Lab. of Dr. Marie-Paule Teulade-Fichou.

2005       CNRS Research fellow (2^nd class, CR2) - CNRS UPR282

Collège de France, Paris, France. Lab. of Pr. Jean-Marie Lehn.

2011       Accreditation to supervise research (Habilitation)

ICMUB, CNRS UMR6302, Dijon, France. 

2004       Post-doctoral fellow CNRS / Sanofi-Aventis grant - CNRS UPR282

Collège de France, Paris, France. Lab. of Prof. Jean-Marie Lehn, under the supervision of Dr. Marie-Paule Teulade-Fichou & Dr. Patrick Mailliet.

2002       Post-doctoral fellow PharmaLEADS grant

Université Paris Descartes, Paris, France. Lab. of Prof. Bernard P. Roques.

1998       Ph.D. in Organic Chemistry

Université Sciences II de Genève, Geneva, Switzerland. Lab. of Prof. Jérôme Lacour

Scientific summary

After a Ph.D in supramolecular chemistry in Geneva (CH), and two post-docs in medicinal chemistry and chemical biology in Paris (FR), I was awarded a position of CNRS researcher in 2005 in the laboratory of Prof. Jean-Marie Lehn (College de France, Paris) under the supervision of Dr. Marie-Paule Teulade-Fichou. Then, I moved with her to the Institut Curie (Orsay, France) from 2007 to 2009, before taking the responsibility of my own research group GATTACA (for Group “nucleic Acids’ Therapeutic & Technological Applications": Chemistry & bio-Analysis) at the Institute of molecular chemistry (ICMUB) in Dijon.

My research is focused on the use of alternative nucleic acid structures (DNA and RNA) as targets for innovative therapies in two areas, cancers and neuropathologies. I published >120 articles (>6900 citations, H-index: 42) in high-impact factors journals (Nat. Commun., Nat. Rev. Chem., JACS, etc.) along with 2 patents (one licensed). My research is supported by various funding agencies including the ANR (e.g., DEMENTIA 2017, InJUNCTION 2022), ITMO Cancer (ANASTOMOSIS 2019), the EU (SEQUENTIA 2019), I-SITE BFC (ANASTASIA 2021), the NIH (G4-in-NVU 2019) and Ligue contre le cancer (OS pediatric 2023).